BIO
Price
$234.63
Change
-$10.89 (-4.44%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
9.79B
21 days until earnings call
QGEN
Price
$40.10
Change
+$0.08 (+0.20%)
Updated
Apr 3, 02:56 PM (EDT)
Capitalization
9.52B
32 days until earnings call
Ad is loading...

BIO vs QGEN

Header iconBIO vs QGEN Comparison
Open Charts BIO vs QGENBanner chart's image
Bio-Rad Laboratories
Price$234.63
Change-$10.89 (-4.44%)
Volume$969
Capitalization9.79B
Qiagen
Price$40.10
Change+$0.08 (+0.20%)
Volume$623
Capitalization9.52B
BIO vs QGEN Comparison Chart
Loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIO vs. QGEN commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and QGEN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (BIO: $245.52 vs. QGEN: $40.02)
Brand notoriety: BIO and QGEN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIO: 74% vs. QGEN: 112%
Market capitalization -- BIO: $9.79B vs. QGEN: $9.52B
BIO [@Medical Specialties] is valued at $9.79B. QGEN’s [@Medical Specialties] market capitalization is $9.52B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 0 FA rating(s) are green whileQGEN’s FA Score has 1 green FA rating(s).

  • BIO’s FA Score: 0 green, 5 red.
  • QGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, QGEN is a better buy in the long-term than BIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 4 TA indicator(s) are bullish while QGEN’s TA Score has 5 bullish TA indicator(s).

  • BIO’s TA Score: 4 bullish, 4 bearish.
  • QGEN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, QGEN is a better buy in the short-term than BIO.

Price Growth

BIO (@Medical Specialties) experienced а +0.08% price change this week, while QGEN (@Medical Specialties) price change was +1.11% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.32%. For the same industry, the average monthly price growth was +1.69%, and the average quarterly price growth was +1.51%.

Reported Earning Dates

BIO is expected to report earnings on Apr 24, 2025.

QGEN is expected to report earnings on May 05, 2025.

Industries' Descriptions

@Medical Specialties (-4.32% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIO($9.79B) and QGEN($9.52B) have the same market capitalization . QGEN has higher P/E ratio than BIO: QGEN (27.85) vs BIO (3.64). QGEN YTD gains are higher at: -7.380 vs. BIO (-25.263). QGEN has higher annual earnings (EBITDA): 689M vs. BIO (-654.76M). BIO has more cash in the bank: 1.61B vs. QGEN (1.06B). BIO has less debt than QGEN: BIO (1.41B) vs QGEN (1.53B). BIO has higher revenues than QGEN: BIO (2.67B) vs QGEN (1.97B).
BIOQGENBIO / QGEN
Capitalization9.79B9.52B103%
EBITDA-654.76M689M-95%
Gain YTD-25.263-7.380342%
P/E Ratio3.6427.8513%
Revenue2.67B1.97B136%
Total Cash1.61B1.06B152%
Total Debt1.41B1.53B92%
FUNDAMENTALS RATINGS
BIO vs QGEN: Fundamental Ratings
BIO
QGEN
OUTLOOK RATING
1..100
2117
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9587
PRICE GROWTH RATING
1..100
6557
P/E GROWTH RATING
1..100
823
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIO's Valuation (79) in the Medical Specialties industry is in the same range as QGEN (84). This means that BIO’s stock grew similarly to QGEN’s over the last 12 months.

QGEN's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as BIO (100). This means that QGEN’s stock grew similarly to BIO’s over the last 12 months.

QGEN's SMR Rating (87) in the Medical Specialties industry is in the same range as BIO (95). This means that QGEN’s stock grew similarly to BIO’s over the last 12 months.

QGEN's Price Growth Rating (57) in the Medical Specialties industry is in the same range as BIO (65). This means that QGEN’s stock grew similarly to BIO’s over the last 12 months.

QGEN's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for BIO (82). This means that QGEN’s stock grew significantly faster than BIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOQGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
45%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
52%
Advances
ODDS (%)
Bullish Trend 14 days ago
69%
Bullish Trend 4 days ago
56%
Declines
ODDS (%)
Bearish Trend 9 days ago
65%
Bearish Trend 9 days ago
50%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 2 days ago
50%
View a ticker or compare two or three
Ad is loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BULZ109.462.35
+2.19%
MicroSectors™ Slct FANG Inn 3X Lvgd ETNs
ISCF33.810.10
+0.30%
iShares MSCI Intl Small-Cap Mltfct ETF
UBT18.460.02
+0.11%
ProShares Ultra 20+ Year Treasury
XLP81.55-0.24
-0.29%
The Consumer Staples Sel SectSPDR® ETF
IDX12.47-0.07
-0.56%
VanEck Indonesia ETF

QGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QGEN has been loosely correlated with A. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if QGEN jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QGEN
1D Price
Change %
QGEN100%
+1.32%
A - QGEN
53%
Loosely correlated
+1.70%
RVTY - QGEN
51%
Loosely correlated
+2.31%
TMO - QGEN
51%
Loosely correlated
+1.26%
DHR - QGEN
47%
Loosely correlated
+2.38%
BIO - QGEN
46%
Loosely correlated
+2.30%
More